Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;35(3):154-161.
doi: 10.2337/cd15-0045.

Metformin Use in Practice: Compliance With Guidelines for Patients With Diabetes and Preserved Renal Function

Gregory J Salber  1 , Yu-Bo Wang  2 , John T Lynch  3 , Karen M Pasquale  3 , Thiruchandurai V Rajan  4 , Richard G Stevens  5 , James J Grady  2 , Anne M Kenny  1
Affiliations

Metformin Use in Practice: Compliance With Guidelines for Patients With Diabetes and Preserved Renal Function

Gregory J Salber et al. Clin Diabetes. 2017 Jul.

Abstract

IN BRIEF Several contraindications limit the use of metformin, most notably the risk of lactic acidosis. This article reports on an examination of a population of patients with diabetes with preserved renal function to evaluate provider compliance with guidelines on metformin use and to identify factors that contributed when practice diverged from recommendations. It found that metformin was withheld from approximately one-third of these patients because of 1) an existent contraindication to metformin, 2) patient behavior or preference, or 3) provider preference or bias based on patient or personal factors. Although providers generally follow current recommendations for the use of metformin, deviations from guidelines in practice are common.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
The percentage of individuals receiving metformin based on A1C level.
FIGURE 2.
FIGURE 2.
The percentage of individuals receiving metformin based on age.
FIGURE 3.
FIGURE 3.
ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications, including ACE or ARB, statin, nonstatin cholesterol medication, other diabetes medications, and insulin.
See this image and copyright information in PMC

References

    1. DPP Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403 - PMC - PubMed
    1. U.K. Prospective Diabetes Study Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865 - PubMed
    1. Rodbard HW, Jellinger PS, Davidson JA, et al. . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540–559 - PubMed
    1. Stang MR, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925–927 - PubMed
    1. Scarpello J, Howlett H. Metformin therapy and clinical uses. Diabetes Vasc Dis Res 2008;5:157–167 - PubMed